This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04812535
Recruitment Status : Active, not recruiting
First Posted : March 23, 2021
Last Update Posted : May 3, 2024
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
InflaRx GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms

Condition or disease Intervention/treatment Phase
SCC - Squamous Cell Carcinoma of Skin Drug: IFX-1 Drug: IFX-1 + pembrolizumab combination therapy Phase 2

Detailed Description:

This is an open-label, non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms (Arm A: IFX-1 monotherapy; Arm B: IFX-1 + pembrolizumab combination therapy), both consisting of 2 stages whereas Arm B starts with a safety run in portion. Enrollment follows an optimal Simon's 2-stage design with an interim analysis of treatment response after Stage 1 prior to patient enrollment into Stage 2.

Arm B will start after ≥3 patients have been treated in Arm A and no toxicity concerns have emerged. In a safety run-in part of Arm B, escalating doses of IFX-1 will be investigated in combination with pembrolizumab in order to identify the MTD or RP2D. Patients will be treated until progression, occurrence of unacceptable toxicity, or treatment discontinuation for any other reason.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Arm A: IFX-1 monotherapy; Arm B: IFX-1 + in combination with approved dosing scheme of pembrolizumab
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
Actual Study Start Date : June 1, 2021
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : December 30, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A: IFX-1 monotherapy
IFX-1 monotherapy
 Drug: IFX-1
IFX-1 Monotherapy
Experimental: Arm B: IFX-1 + pembrolizumab combination therapy
IFX-1 + pembrolizumab combination therapy
 Drug: IFX-1 + pembrolizumab combination therapy
IFX-1 + pembrolizumab combination therapy
Other Name: KEYTRUDA®


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. ORR- Arm A [ Time Frame: Up to 36 months ]
    Investigator assessed best overall response rate (ORR) for IFX-1, with response being defined as best response of CR/confirmed CR (iCR) or PR/confirmed PR (iPR) per modified RECIST v1.1/iRECIST

  2. DLT- Arm B [ Time Frame: Cycle 1 Day - Cycle 1 Day 36 ]
    Frequency of dose-limiting toxicities (DLTs) by dose cohort

  3. ORR- Arm B [ Time Frame: Up to 36 months ]
    Investigator assessed best ORR for IFX-1 + pembrolizumab, with response being defined as best response of CR/confirmed CR (iCR) or PR/confirmed PR (iPR) per modified RECIST v1.1/iRECIST

  4. TEAEs- Arm B [ Time Frame: Up to 36 months ]
    Frequency, severity, and investigational new drug (IND) attribution of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) according to Medical Dictionary for Regulatory Activities (MedDRA) coding (version valid at time of reporting) and the NCI CTCAE grading system (version 5.0, 27 November 2017)


Secondary Outcome Measures :
  1. Disease control rate - Arm A [ Time Frame: Up to 36 months ]
    Disease control rate (CR/iCR+PR/iPR+SD)

  2. Progression-free survival (PFS)- Arm A [ Time Frame: Up to 36 months ]
    Progression free survival

  3. Overall survival (OS)- Arm A [ Time Frame: Up to 36 months ]
    Overall survival (OS)

  4. TEAEs- Arm A [ Time Frame: Up to 36 months ]
    Frequency, severity, and IND attribution of TEAEs and SAEs according to MedDRA coding (version valid at time of reporting) and the NCI CTCAE grading system v5.0

  5. ADAs- Arm A [ Time Frame: Up to 27 months ]
    Development of human antidrug antibodies (ADAs) against IFX-1

  6. QoL- Arm A [ Time Frame: Up to 36 months ]
    Changes in QoL as per the European Organisation for Research and Treatment of Cancer (EORTC)-QoL questionnaire (QLQ)-C30 total score

  7. Response (CR/iCR/PR/iPR) and SD- Arm B [ Time Frame: Up to 36 months ]
    Response (CR/iCR/PR/iPR) and SD duration

  8. Disease control rate- Arm B [ Time Frame: Up to 36 months ]
    Disease control rate (CR/iCR+PR/iPR+SD)

  9. Progression free survival- Arm B [ Time Frame: Up to 36 months ]
    Progression free survival-

  10. Overall survival- Arm B [ Time Frame: Up to 36 months ]
    Overall survival

  11. QoL - Arm B [ Time Frame: Up to 36 months ]
    Quality of Life

  12. ADAs against IFX-1 - Arm B [ Time Frame: Up to 36 months ]
    Development of human ADAs against IFX-1


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age on day of signing informed consent
  • Patients with biopsy-proven, histologically or cytologically confirmed (a.) locally advanced cSCC not amenable for curative treatment or (b.) metastatic cSCC. Patients must have been treated with all approved therapies for (a.) inoperable locally advanced cSCC contraindicated for radiation therapy or (b.) metastatic cSCC
  • Eastern Cooperative Oncology Group performance status (ECOG PS) status of ≤1
  • Patients must have progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.
  • Patient provides written informed consent for the study.

Exclusion Criteria:

  • Patients with limited cSCC, who do not require systemic therapy
  • Has a diagnosis of immunodeficiency or autoimmune disease, or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 3 weeks prior the first dose of study treatment
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab or IFX-1 and/or any of their excipients or had a severe (≥Grade 3) infusion-related reaction to treatments with other mAbs
  • Patients who have undergone major surgery <4 weeks prior to starting study treatment
  • Patients with known ≥Grade 3 (per National Cancer Institute common terminology criteria for adverse events [NCI CTCAE] v5.0 criteria) active systemic or cutaneous viral, bacterial, or fungal infection
  • Has known active central nervous system metastases and/or carcinomatous meningitis.
  • Patients with a history of other malignancies during the past 5 years
  • Patients with congestive heart failure, Class III or IV, by New York Heart Association criteria
  • Patients who are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study,
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04812535


Locations
Show Show 25 study locations
Sponsors and Collaborators
InflaRx GmbH
Merck Sharp & Dohme LLC
Investigators
Layout table for investigator information
Principal Investigator: Prof. Dr. D. Schadendorf, MD University Hospital, Essen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: InflaRx GmbH
ClinicalTrials.gov Identifier: NCT04812535    
Other Study ID Numbers: IFX-1 P2.8
MK-3475-A93 ( Other Identifier: Merck Sharp & Dohme LLC )
KEYNOTE-A93 ( Other Identifier: Merck Sharp & Dohme LLC )
2020-000864-42 ( EudraCT Number )
First Posted: March 23, 2021    Key Record Dates
Last Update Posted: May 3, 2024
Last Verified: May 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by InflaRx GmbH:
cSCC
metastatic
locally advanced
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Pembrolizumab
Vilobelimab
 Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs